These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 38432935)
1. [Prediction of Cardiac Toxicity by Anti-cancer Drugs Using iPSC Cardiomyocytes]. Yanagida S; Kanda Y Yakugaku Zasshi; 2024; 144(3):265-271. PubMed ID: 38432935 [TBL] [Abstract][Full Text] [Related]
2. [Cardiotoxicity risk assessment of anti-cancer drugs and future perspectives]. Yanagida S; Kawagishi H; Kanda Y Nihon Yakurigaku Zasshi; 2024; 159(2):83-89. PubMed ID: 38432924 [TBL] [Abstract][Full Text] [Related]
3. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity. Yang X; Papoian T J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688 [TBL] [Abstract][Full Text] [Related]
4. Chronic cardiotoxicity assessment of BMS-986094, a guanosine nucleotide analogue, using human iPS cell-derived cardiomyocytes. Yanagida S; Satsuka A; Hayashi S; Ono A; Kanda Y J Toxicol Sci; 2021; 46(8):359-369. PubMed ID: 34334557 [TBL] [Abstract][Full Text] [Related]
5. Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs). Narkar A; Willard JM; Blinova K Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328619 [TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology. Satsuka A; Kanda Y Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543 [TBL] [Abstract][Full Text] [Related]
7. Speckle-Tracking Strain Analysis for Mapping Spatiotemporal Contractility of Induced Pluripotent Stem Cell (iPSC)-Derived Cardiomyocytes. Izadifar M; Berecz T; Li B; Tang JKKY; Foldes G; Apati A; Nagy A Curr Protoc; 2023 Sep; 3(9):e889. PubMed ID: 37747346 [TBL] [Abstract][Full Text] [Related]
8. [Evaluation of Contractile Function Using Human iPS Cell-derived Cardiomyocytes]. Kurokawa J; Shimizu S; Sakamoto K Yakugaku Zasshi; 2024; 144(3):251-255. PubMed ID: 38432933 [TBL] [Abstract][Full Text] [Related]
9. Proarrhythmia Risk Assessment Using Electro-Mechanical Window in Human iPS Cell-Derived Cardiomyocytes. Yanagida S; Satsuka A; Hayashi S; Ono A; Kanda Y Biol Pharm Bull; 2022; 45(7):940-947. PubMed ID: 35786601 [TBL] [Abstract][Full Text] [Related]
10. An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility. Scott CW; Zhang X; Abi-Gerges N; Lamore SD; Abassi YA; Peters MF Toxicol Sci; 2014 Dec; 142(2):331-8. PubMed ID: 25237062 [TBL] [Abstract][Full Text] [Related]
11. Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Matsui T; Miyamoto K; Yamanaka K; Okai Y; Kaushik EP; Harada K; Wagoner M; Shinozawa T Toxicol Appl Pharmacol; 2019 Nov; 383():114761. PubMed ID: 31533062 [TBL] [Abstract][Full Text] [Related]
12. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Liang P; Lan F; Lee AS; Gong T; Sanchez-Freire V; Wang Y; Diecke S; Sallam K; Knowles JW; Wang PJ; Nguyen PK; Bers DM; Robbins RC; Wu JC Circulation; 2013 Apr; 127(16):1677-91. PubMed ID: 23519760 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive Cardiotoxicity Assessment of COVID-19 Treatments Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Yanagida S; Satsuka A; Hayashi S; Ono A; Kanda Y Toxicol Sci; 2021 Aug; 183(1):227-239. PubMed ID: 34142159 [TBL] [Abstract][Full Text] [Related]
14. Bufalin-induced cardiotoxicity: new findings into mechanisms. Li M; Wang XJ; Zhao Q; Wang JX; Xing HY; Zhang YZ; Zhang XX; Zhi YY; Li H; Ma J Chin J Nat Med; 2020 Jul; 18(7):550-560. PubMed ID: 32616195 [TBL] [Abstract][Full Text] [Related]
15. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes. Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414 [TBL] [Abstract][Full Text] [Related]
17. In-depth mechanistic analysis including high-throughput RNA sequencing in the prediction of functional and structural cardiotoxicants using hiPSC cardiomyocytes. Rosell-Hidalgo A; Bruhn C; Shardlow E; Barton R; Ryder S; Samatov T; Hackmann A; Aquino GR; Fernandes Dos Reis M; Galatenko V; Fritsch R; Dohrmann C; Walker PA Expert Opin Drug Metab Toxicol; 2024 Jul; 20(7):685-707. PubMed ID: 37995132 [TBL] [Abstract][Full Text] [Related]
18. An In Silico Platform to Predict Cardiotoxicity Risk of Anti-tumor Drug Combination with hiPSC-CMs Based In Vitro Study. Sang L; Zhou Z; Luo S; Zhang Y; Qian H; Zhou Y; He H; Hao K Pharm Res; 2024 Feb; 41(2):247-262. PubMed ID: 38148384 [TBL] [Abstract][Full Text] [Related]
19. Machine-learning-based quality control of contractility of cultured human-induced pluripotent stem-cell-derived cardiomyocytes. Orita K; Sawada K; Matsumoto N; Ikegaya Y Biochem Biophys Res Commun; 2020 Jun; 526(3):751-755. PubMed ID: 32265031 [TBL] [Abstract][Full Text] [Related]
20. Effects of Electrical Stimulation on hiPSC-CM Responses to Classic Ion Channel Blockers. Wei F; Pourrier M; Strauss DG; Stockbridge N; Pang L Toxicol Sci; 2020 Apr; 174(2):254-265. PubMed ID: 32040191 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]